ObjectiveTo explore the effect of recombinant human follicle-stimulating hormone (rhFSH) on serum hormone level, ovulation, and pregnancy rate in patients with polycystic ovary syndrome (PCOS). MethodA total of 104 patients with PCOS who were treated in our hospital from June 2017 to May 2018 were selected as the research objects. The patients were divided into two groups using the random number method, with 52 cases in each group. The control group was given clomiphene for treatment, whereas the observation group was additionally administered rhFSH based on the treatment in the control group, for a ten-day treatment course. The clinical efficacy, serum hormone level, cervical mucus scores, endometrial thickness, ovulation rate, pregnancy rate, and occurrence of adverse reactions were compared between the two groups. ResultsTwelve-month follow-up after the end of treatment, the total effective rate of treatment in the observation group (90.38%) was significantly higher than that in the control group (73.08%), with a statistically significant difference (P＜0.05). At the 21st day of the menstrual cycle, the levels of follicle-stimulating hormone (FSH), progesterone (P), and estradiol (E2) significantly increased in the two groups, and the levels of the observation group were significantly higher than those of the control group, with statistically significant differences (P＜0.05). After 10 days of treatment, the cervical mucus scores and the endometrial thickness of the two groups significantly increased, and patients in the observation obtained higher cervical mucus scores, as well as a larger endometrial thickness as compared with the control group, with statistically significant differences (P＜0.05). The ovulation rate (65.38%) of the menstrual cycle in the observation group was significantly higher than that in the control group (36.54%). After 12 months of follow-up, the pregnancy rate of the observation group (30.77%) was significantly higher than that of the control group (13.46%), with a statistically significant difference (P＜0.05). During treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionRecombinant human follicle-stimulating hormone therapy for patients with PCOS is beneficial to improve the serum hormone level, promote ovulation, increase the pregnancy rate of patients, and thus it is highly safe for treatment.

无